XenaCare Holdings Announces Availability of Cobroxin Through the Chain Drug Marketing Association (CDMA)
XenaCare Holdings has announced that Chain Drug Marketing Association (CDMA) will begin stocking Cobroxin for distribution and sale through its 135 retail and wholesale members of regional and independent drug stores, representing over 6,000 outlets nationally.
Delray Beach, FL, November 10, 2009 --(PR.com)-- XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. CDMA currently communicates with over 135 buying headquarters that total over 6,000 outlets in 32 states.
“As one of the largest pharmacy organizations in the United States, we are excited to be working with CDMA to distribute Cobroxin to its independent pharmacy members,” explained Frank Rizzo, President of XenaCare Holdings. “Having a presence with CDMA will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign,” he concluded.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
· All Natural
· Non-Addictive
· Non-Narcotic
· Non-Opiate
· More Potent than Morphine
· Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.XenaCareHoldings.com
http://www.Cobroxin.com
Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans to introduce Cobroxin into the commercial marketplace and for additional marketing campaigns are forward looking statements. Although these forward looking statements constitute our current plans, the timing, marketing channels and advertising support for the product may change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
###
“As one of the largest pharmacy organizations in the United States, we are excited to be working with CDMA to distribute Cobroxin to its independent pharmacy members,” explained Frank Rizzo, President of XenaCare Holdings. “Having a presence with CDMA will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign,” he concluded.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
· All Natural
· Non-Addictive
· Non-Narcotic
· Non-Opiate
· More Potent than Morphine
· Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.XenaCareHoldings.com
http://www.Cobroxin.com
Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans to introduce Cobroxin into the commercial marketplace and for additional marketing campaigns are forward looking statements. Although these forward looking statements constitute our current plans, the timing, marketing channels and advertising support for the product may change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
###
Contact
XenaCare Holdings
Frank Rizzo
561-496-6676
www.xenacare.com
Frank Rizzo
561-496-6676
www.xenacare.com
Contact
Categories